Acucela Inc.

Eolas Therapeutics, Inc.

Merck Sharp + Dohme Corp.

University of Washington

Fred Hutchinson Cancer Center

Agenebio, Inc.

University of Michigan

Icos Corporation

Deltagen Research Labs, LLC

Fred Hutchinson Cancer Research Center

Qin Jiang

Robert Jason Herr

Ryo Kubota

Mark W Orme

Ian L Scott

Jennifer Lynn Gage

Anna S Gall

Thomas L Little, Jr

Lana Michele Rossiter

Kevin F McGee, Jr

Theodore M Kamenecka

Emily Elizabeth Freeman

Yuanjun He

Nicholas James Mayhew

Xinyi Song

Rong Jiang

William Nguyen

Anandan Palani

Robert G Aslanian

John Anthony Butera

Graham Johnson

Xianhai Huang

Kevin D McCormick

Dong Xiao

Hongjun Zhang

Vladimir Aleksandrovich Kuksa

Younong Yu

Joey Lee Methot

Phieng Siliphaivanh

Christopher W Boyce

Purakkattle J Biju

Robert D Mazzola, Jr

Ashwin Umesh Rao

Jun Qin

Jianxing Huang

Elizabeth Helen Kelley

Julian Simon

Belew Mekonnen

Li Dong

Xinchao Chen

Pawan Dhondi

R Jason Herr

Hemantbhai Patel

Edwin W Rubel

David W Raible

Sarwat Chowdhury

Kelly N Owens

Jolicia Polivina Gauuan

Vladimir Aleksandrovich Kuska

Andrew J Leyhane

Brian Alexander McKittrick

Kerry W Fowler

Neil Moss

James A Shayman

Scott D Larsen

Jaimie Karyn Rueter

Xiao Chen

John P Caldwell

Wei Zhou

Danwen Huang

Haiqun Tang

Pavel E Zhichkin

Graham Beaton

Salem Fevrier

Henry M Vaccaro

Ning Shao

Rachel Nicola MacCoss

Wilna J Moree

Russell Dahl

Sylvia Joanna Degrado

Jie Wu

William Colby Brown

David L McElligott

Kim Hutchings

David John Fairfax

Phyllis S Goldman

Erik Christenson

Helge A Reisch

Lisa H Bourdon

Zohreh Sajjadi Hashemi

Anthony J Demaggio

Dan Herendeen

Jaimie E Bertino

Ren Hua Song

Robert D Mazzola

Rachel N Maccoss

Kevin D Mccormick

Brian A Mckittrick

Pawan K Dhondi

Purakkattle Johny Biju

Joe Lee Method

Kevin D Mccormic

Robert George Aslanian

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAreceptor agonist (e.g., an α5-containing GABAreceptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAreceptor agonist (e.g., an α5-containing GABAreceptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an &#x3b1;5-containing GABAreceptor agonist (e.g., an &#x3b1;5-containing GABAreceptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an &#x3b1;5-containing GABAreceptor agonist (e.g., an &#x3b1;5-containing GABAreceptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

Glucosylceramide synthase inhibitors and therapeutic methods using the same

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Styrenyl derivative compounds for treating ophthalmic diseases and disorders

Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing, treating, and/or protecting against sensory hair cell death. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.

Compounds and methods for preventing, treating and/or protecting against sensory hair cell death

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OXor OX, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.

Substituted prolines/piperidines as orexin receptor antagonists

Substituted prolines / piperidines as orexin receptor antagonists

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula:or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q, Qand Y are those defined herein.

PARP inhibitors

Growing community of inventors

Latham, NY, United States of America

Qin Jiang